Screening for prostate cancer at low PSA range: The impact of digital rectal examination on tumor incidence and tumor characteristics

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Prostate

• Publication date

  2007-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pros.20501PMID 17044079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55–75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam)

  2006cited by this paper
• Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.

  2005cited by this paper
• Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

  2005cited by this paper
• Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

  2004cited by this paper
• Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

  2004cited by this paper
• European Randomized Study of Screening for Prostate Cancer: achievements and presentation

  2003cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

  2003cited by this paper
• Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.

  2003cited by this paper
• Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: An autopsy study

  2003cited by this paper
• Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

  2002cited by this paper
• Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

  2001influential reference
• How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival?

  2001cited by this paper
• Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0–3.9 ng/ml)

  2001cited by this paper
• Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

  2000cited by this paper
• Epidemiology and molecular biology of early prostatic neoplasia.

  2000cited by this paper
• Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)

  1999influential reference
• Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam)

  1999influential reference
• Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

  1999cited by this paper
• Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer

  1998cited by this paper
• Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

  1997cited by this paper
• Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate.

  1997cited by this paper
• The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

  1994cited by this paper
• Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

  1994cited by this paper
• Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

  1994cited by this paper
• Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer

  1993cited by this paper
• Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer.

  1991cited by this paper
• Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma.

  1989cited by this paper
• Latent prostatic cancer in a consecutive autopsy series.

  1980cited by this paper

• Digital rectal exam in prostate cancer screening: a critical review of the ERSPC Rotterdam study

  2024influential citation
• Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators

  2023cites this paper
• NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.

  2023cites this paper
• An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.

  2023cites this paper
• A cable driven robotic palpation system with contact force sensing based on cable tension observation

  2022cites this paper
• UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.

  2022cites this paper
• Hypoehoic lesions on Transrectal Ultrasound and its correlation to Gleason grade in the diagnosis of Clinically Significant Prostate Cancer: A Prospective Study

  2021cites this paper
• Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial

  2021cites this paper
• Development of a tendon driven robotic probe for prostate palpation

  2021cites this paper
• Coronavirus disease 2019 and the cancellation of face-to-face prostate cancer active surveillance clinic reviews: Does the omission of digital rectal examination alone put patients at risk of missed detection of disease progression?

  2021cites this paper
• The times they are a-changin': The evolution of prostate cancer screening practices and beliefs among primary care physicians in Victoria, British Columbia.

  2020cites this paper
• Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm

  2017cites this paper
• Recommandations de l'Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.

  2017cites this paper
• Anti-proliferative and apoptotic action of sophocarpine in human prostate cancer cell lines

  2017cites this paper
• Hypoechoic lesions on transrectal ultrasonography as a marker for clinically significant prostate cancer

  2016cites this paper
• What's new in screening in 2015?

  2016cites this paper
• B-Mode and Acoustic Radiation Force Impulse (ARFI) Imaging of Prostate Zonal Anatomy

  2015cites this paper
• Prevalence of high-grade or insignificant prostate cancer in Korean men with prostate-specific antigen levels of 3.0-4.0 ng/mL.

  2015cites this paper
• Oxymatrine inhibits the proliferation of prostate cancer cells in vitro and in vivo

  2015cites this paper
• Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination

  2015cites this paper
• microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7.

  2015cites this paper
• Digital rectal examination in a simulated environment using sweeping palpation and mechanical localization

  2014cites this paper
• Digital rectal examination in a simulated environment using sweeping palpation and mechanical localization

  2014cites this paper
• Advanced 2D machine palpation for tissue abnormality localization in a simulated environment

  2013cites this paper
• Discovery and validation of prostate cancer biomarkers

  2013cites this paper
• Are Hypoechoic Lesions on Transrectal Ultrasonography a Marker for Clinically Significant Prostate Cancer?

  2013cites this paper
• The prostate exam

  2012cites this paper
• Early detection of high‐grade prostate cancer using digital rectal examination (DRE) in men with a prostate‐specific antigen level of <2.5 ng/mL and the risk of death

  2012cites this paper
• Robotic Palpation-Based Mechanical Property Mapping for Diagnosis of Prostate Cancer

  2011cites this paper
• Experimental Endourology Robotic Palpation-Based Mechanical Property Mapping for Diagnosis of Prostate Cancer

  2011cites this paper
• Robotic system for hybrid diagnosis of prostate cancer: Design and experimentation

  2011cites this paper
• The Performance of Abnormal Digital Rectal Examination for the Detection of Prostate Cancer at Stratified Prostate Specific Antigen Levels

  2011cites this paper
• Predictive value of digital rectal examination for prostate cancer detection is modified by obesity

  2011cites this paper
• Comparison of Observed Biochemical Recurrence Free Survival in Patients with Low PSA Values Undergoing Radical Prostatectomy to the Predictions of a Preoperative Nomogram

  2010cites this paper
• Robotic palpation system for prostate cancer detection

  2010cites this paper
• The Value of Digital Rectal Examination in Men With Lower Urinary Tract Symptoms and Prostate-Specific Antigen < 3 ng/mL

  2010cites this paper
• Early detection and screening for prostate cancer

  2010cites this paper
• Bevolkingsonderzoek naar prostaatkanker

  2009cites this paper
• Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.

  2008cites this paper
• Digital rectal examination remains an important screening tool for prostate cancer.

  2008cites this paper
• Screening for Prostate Cancer: Digital rectal examination: outdated or still valuable?

  2008cites this paper
• Defining the Problem: From Subclinical Disease to Clinically Insignificant Prostate Cancer

  2008cites this paper
• Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.

  2008cites this paper
• Percent free prostate‐specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower

  2008cites this paper
• Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging.

  2008cites this paper
• Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.

  2008cites this paper
• [Incidence of locally invasive prostate cancer in patients with intermediate values of prostate-specific antigen].

  2007cites this paper
• Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer

  2007cites this paper
• White Paper : To Screen or Not to Screen ?

  year unknowncites this paper
• Prostate Cancer Early Detection, Version 1.2023 Featured Updates to the NCCN Guidelines

  year unknowncites this paper